Novartis’ Kisqali Could Challenge Pfizer’s Ibrance After Phase II First-Line Aggressive Breast Cancer Success

Novartis AG’ Kisqali has met the primary endpoint in a Phase II trial in first-line use in aggressive metastatic breast cancer trial which could boost off-label use in this setting as the Swiss major challenges rival Pfizer Inc.’s Ibrance in a highly anticipated pivotal trial.

RIGHT Choice set the CDK4/6 inhibitor Kisqali (ribociclib) plus endocrine therapy (ET) against combination chemotherapy in 222 pre- and peri-menopausal women with first-line aggressive HR+/HER2− metastatic breast cancer. More than...